Actively Recruiting
Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
Led by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · Updated on 2025-11-06
32
Participants Needed
2
Research Sites
187 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study will evaluate the safety, tolerability, and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors. Participants will be enrolled in one of 4 ascending-dose cohorts. Each treatment cycle will consist of multiple intravenous (IV) doses. Dose escalation decisions will be based on data collected during the dose-limiting toxicity (DLT) period.
CONDITIONS
Official Title
Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Documented locally advanced or metastatic solid tumor malignancy or non-Hodgkin's lymphoma
- Cancer that is refractory to, progressed after, relapsed after, or intolerant to standard therapy known to benefit their condition, or with no available standard therapy
- Measurable disease according to RECIST version 1.1
- Malignancy not suitable for surgical treatment
- ECOG performance status of 0, 1, or 2
- Anticipated life expectancy of at least 3 months at consent
- Other protocol-defined inclusion criteria may apply
You will not qualify if you...
- Known central nervous system or leptomeningeal metastases not controlled by prior surgery or radiotherapy
- Symptoms indicating central nervous system involvement requiring treatment
- Other protocol-defined exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
NEXT Oncology
Irving, Texas, United States, 75039
Actively Recruiting
2
Next Oncology
San Antonio, Texas, United States, 78229
Actively Recruiting
Research Team
N
Novo Nordisk
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here